The family of inflammatory/autoimmune systemic diseases (IAD) form a continuum from pure inflammatory diseases to pure autoimmune diseases, encompassing a large panel of inflammatory diseases with some autoimmune components, and vice versa. Cross phenotyping of patients with IAD should be heuristic and help revise the nosography and the understanding of these diseases.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Total peripheral blood gene expression between patients, expressed as fluorescence intensity
Timeframe: at day 0, no follow-up
Tregs and Tconvs T cell receptor repertoire, expressed as the % of unique TCR sequences
Timeframe: at day 0, no follow-up
HLA type and SNPs expressed as the occurrence events across patients
Timeframe: at day 0, no follow-up
Microbiote species identification expressed as the % of species per family and genus
Timeframe: at day 0, no follow-up
Cytokines and chemokines expressed as fluorescence intensity
Timeframe: at day 0, no follow-up
Immune cells phenotyping expressed as the each cell type % within total PBMCs
Timeframe: at day 0, no follow-up